ClinicalTrials.gg
RecruitingNCT07595003Updated May 19, 2026

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

A Phase 3 interventional study of 4-MUST and Placebo in Chronic Cholecystitis and Biliary Dyskinesia, sponsored by Valenta Pharm JSC. Recruiting at 10 sites in Russia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2025, registered May 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

02

Conditions studied

  • Chronic Cholecystitis
  • Biliary Dyskinesia
03

In context

Lead sponsor

Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18-70 years.
  2. Diagnosed with chronic cholecystitis (K81.1) and/or dyskinesia of the cystic duct or gallbladder (K82.8) prior to enrollment; diagnosis supported by clinical history of exacerbations and remissions and/or imaging/laboratory findings.
  3. Upper abdominal pain or discomfort attributable to gallbladder or biliary tract dysfunction (per investigator assessment), accompanied by ≥1 of the following: heartburn, belching, nausea, abdominal bloating, borborygmi (stomach rumbling), flatulence, constipation, or diarrhea.
  4. Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
  5. Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
  6. The total level does not exceed 2 times the (no more than 42 μmol/L).
  7. Women who are either sexually abstinent or using effective methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
  8. Signed and dated from.

Non-inclusion Criteria:

  1. Gastric or duodenal ulcer, erosive gastroesophageal reflux disease (GERD), or other inflammatory/erosive gastrointestinal diseases in the acute stage, unless stable remission for ≥ 1 year since the last exacerbation.
  2. Indication for surgical or endoscopic intervention due to exacerbation of chronic cholecystitis or complications of biliary tract dyskinesia.
  3. Toxic megacolon.
  4. Paralytic ileus.
  5. Gilbert's syndrome.
  6. Choledocholithiasis (or a high risk of its development, as determined by the investigator);
  7. Impaired bile outflow due to adhesions in the abdominal cavity.Abdominal adhesion disease.
  8. Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
  9. Gastrointestinal (including history of) or suspected gastrointestinal malignancy (e.g., blood in stool, unexplained weight loss, fever, anemia).
  10. Any other oncological diseases known at the time of screening, or suspicion thereof.
  11. History of gastrointestinal surgery, including cholecystectomy or endoscopic sphincterotomy (appendectomy excluded).
  12. Use of prohibited therapy medications within 3 days prior to randomization.
  13. History of mental illnesses.
  14. Chronic heart failure IIb-III stages and/or III-IV functional classes according to , angina pectoris III-IV functional classes.
  15. Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
  16. History of or current hepatic impairment; or liver test abnormalities: , ALT, ALP, or GGT >3 above the upper limit of normal (ULN); total bilirubin >2 ULN or clinical jaundice.
  17. , syphilis, viral or C, including in history.
  18. Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
  19. Liver cirrhosis.
  20. to the active ingridient or any of the of the drug 4-MUST.
  21. Severe, decompensated, or unstable somatic conditions that are life-threatening, worsen prognosis, or preclude safe study participation.
  22. Diabetes mellitus in a state of subcompensation and decompensation.
  23. Systemic connective tissue diseases.
  24. diseases.
  25. Indication for hemodialysis procedures.
  26. Epilepsy or seizures of unclear etiology, including in history.
  27. Alcoholism, substance abuse or drug addiction, including in history.
  28. Uncorrected electrolyte disturbances.
  29. interval on a 12-lead (ECG) ≥430 ms in men and ≥450 ms in women.
  30. Episodes of constipation during the last 3 months that required the prescription of drug therapy.
  31. History of surgery within 6 month prior to screening.
  32. Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
  33. Patients who require prohibited concomitant therapy within this study framework.
  34. Participation in another clinical trial within the last 3 months prior to the screening visit date.
  35. Unwillingness or inability to comply with study procedures and protocol requirements..
  36. Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
  2. Lack of Efficacy. Study treatment will be discontinued if no clinical improvement is observed by Visit 3 (Day 15 ± 1), defined as persistence or worsening of upper abdominal pain/discomfort (assessed by Visual Analog Scale [VAS]) compared to baseline. Upon discontinuation, alternative therapy will be initiated at the investigator's discretion.
  3. Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
  4. Requirement for prohibited concomitant therapy.
  5. Use of Duspatalin® (INN: mebeverine) for more than 3 consecutive days or for more than 5 days in total throughout the study.
  6. If the investigator judges that comtinued participation in the study would harm the patient.
  7. Pregnancy or the need for breastfeeding.
  8. Major protocol deviation by the subject with respect to procedures outlined in the Form (ICF).
  9. Withdrawal of informed consent by the subject (decision to discontinue study participation).
  10. Lost to follow-up: Inability to contact the subject after ≥3 documented attempts via mobile phone, landline (if applicable), and designated emergency contact.
  11. Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
  12. Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    4-MUST

    4-MUST: 384 mg (3 tablets), orally three times a day (TID), 30 min before meals. Total daily dose - 1152 mg.

    Drug: 4-MUST

  • Placebo comparator
    Placebo

    Placebo: 3 tablets, orally three times a day (TID), 30 min before meals.

    Drug: Placebo

Interventions

  • Drug4-MUST

    128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.

    Also known as: trimebutine 4-methylumbelliferyl sulfate

  • DrugPlacebo

    Placebo tablet.

06

What researchers measure

Primary outcomes

  1. Mean reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 29 ± 1

Secondary outcomes

  1. Mean reduction in the severity of pain/discomfort in the upper abdomen according to VAS by days 2-28 from the start of therapy

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 2 - Day 28

  2. Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more) by days 8, 15, 22, and 29 following treatment initiation.

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  3. Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more) by days 8, 15, 22, and 29 following treatment initiation.

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  4. Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more)

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 29 ± 1

  5. Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more)

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 29 ± 1

  6. Frequency of clinical recovery (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less) by days 8, 15, 22, and 29 following treatment initiation.

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  7. Time to clinical recovery (reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less)

    Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"

    Time frame: Day 29 ± 1

  8. Change in the total score of gastroenterological symptom severity according to the GSRS questionnaire by days 8, 15, 22, and 29 following treatment initiation.

    The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  9. Change in dyspeptic symptom severity, as assessed by the GSRS, expressed as score changes from baseline in the Abdominal Pain, Reflux, Indigestion, Diarrhea, and Constipation syndrome subscales at Days 8, 15, 22, and 29 following treatment initiation.

    The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  10. Change in the severity of individual symptoms of dyspeptic disorders according to the GSRS questionnaire in points by days 8, 15, 22, and 29 following treatment initiation.

    The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  11. Change in quality of life according to the total score on the SF-36 questionnaire by day 29 from treatment initiation.

    SF-36 (Short Form 36 Health Survey) is a self-reported questionnaire. It consists of 36 items that cover eight health domains: Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Bodily pain, General health perceptions, Vitality (energy and fatigue), Social functioning, Mental health. SF-36 produces a profile of scores for each domain, which can be summarized into two main components: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, where lower scores indicate greater disability and higher scores indicate better health.

    Time frame: Day 29 ± 1

  12. Change in the total score on the PAGI-SYM questionnaire by days 15 and 29 from treatment initiation.

    PAGI-SYM (Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index) is a patient-reported questionnaire designed to assess the severity of symptoms in upper gastrointestinal disorders (GERD, dyspepsia, and gastroparesis). It consists of 20 items grouped into six subscales: Heartburn/Regurgitation, Fullness/Early Satiety, Nausea/Vomiting, Bloating, Upper Abdominal Pain, and Lower Abdominal Pain. Each symptom is rated on a 6-point Likert scale from 0 (none) to 5 (very severe). The questionnaire provides a profile of scores for each subscale, as well as a total score. Higher scores indicate greater symptom severity.

    Time frame: Day 15 ± 1, and 29 ± 1

  13. change in the total score on the Visceral Sensitivity Index questionnaire by days 15 and 29 from the start of therapy

    VSI (Visceral Sensitivity Index) is a patient-reported questionnaire measuring gastrointestinal-specific anxiety (cognitive, affective, and behavioral responses to GI sensations). It consists of 15 items rated on a 6-point scale, producing a total score from 0 to 75. Higher scores indicate greater GI-specific anxiety. Originally validated in IBS patients, it is now used across various GI disorders.

    Time frame: Day 15 ± 1, and 29 ± 1

  14. Change in the total score on the Emotional Distress - Depression - Short Form 4a questionnaire by days 8, 15, 22, and 29 from the start of therapy

    Emotional Distress - Depression - Short Form 4a (PROMIS Depression SF 4a) is a patient-reported questionnaire assessing depression symptoms over the past 7 days. It consists of 4 items rated on a 5-point scale. Raw scores (4-20) are converted to a standardized T-score (mean=50, SD=10). Higher scores indicate greater depression severity.

    Time frame: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1

  15. Safety and Tolerability: adverse event (AE) rate

    Frequency of adverse events (AEs) or serious AEs (SAEs)

    Time frame: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)

  16. Safety and Tolerability: adverse event (AE) number

    Number of adverse events (AEs) or serious AEs (SAEs)

    Time frame: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)

  17. Safety and Tolerability: AEs associated with the study drug

    Number and frequency of AEs associated with the study drug

    Time frame: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)

  18. Safety and Tolerability: SAEs associated with the study drug

    Number and frequency of SAEs associated with the study drug

    Time frame: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)

  19. Safety and Tolerability: treatment discontinuation

    Percentage of patients who discontinued treatment due to the occurrence of AEs/SAEs

    Time frame: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)

  20. Safety and Tolerability: vital signs - systolic blood pressure (SBP)

    SBP, mmHg

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  21. Safety and Tolerability: vital signs - diastolic blood pressure (DBP)

    DBP, mmHg

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  22. Safety and Tolerability: vital signs - respiratory rate (RR)

    RR, breaths per minute

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  23. Safety and Tolerability: vital signs - heart rate (HR)

    HR, beats per minute

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  24. Safety and Tolerability: vital signs - body temperature

    Body temperature, Celsius scale

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  25. Physical examination results: cardiovascular system

    An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  26. Physical examination results: respiratory system

    An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  27. Physical examination results: digestive tract

    An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  28. Physical examination results: endocrine system

    An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  29. Physical examination results: musculoskeletal system

    An assessment of the condition of the musculoskeletal system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  30. Physical examination results: nervous system

    An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  31. Physical examination results: sensory systems

    An assessment of the condition of the sensory systems on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  32. Physical examination results: skin/visible mucous membranes

    An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1

  33. Results of laboratory and instrumental examinations: clinical blood test - hemoglobin

    Hemoglobin (g/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  34. Results of laboratory and instrumental examinations: clinical blood test - hematocrit

    Hematocrit (%)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  35. Results of laboratory and instrumental examinations: clinical blood test - red blood cell count

    Red blood cell count (cells/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  36. Results of laboratory and instrumental examinations: clinical blood test - platelet count

    Platelet count (cells/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  37. Results of laboratory and instrumental examinations: clinical blood test - leukocyte count

    Leukocyte count (cells/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  38. Results of laboratory and instrumental examinations: clinical blood test - erythrocyte sedimentation rate

    Erythrocyte sedimentation rate (mm/h)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  39. Results of laboratory and instrumental examinations: clinical blood test - myelocytes

    Leukocyte formula (myelocytes, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  40. Results of laboratory and instrumental examinations: clinical blood test - band neutrophils

    Leukocyte formula (band neutrophils, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  41. Results of laboratory and instrumental examinations: clinical blood test - segmented neutrophils

    Leukocyte formula (segmented neutrophils, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  42. Results of laboratory and instrumental examinations: clinical blood test - eosinophils

    Leukocyte formula (eosinophils, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  43. Results of laboratory and instrumental examinations: clinical blood test - basophils

    Leukocyte formula (basophils, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  44. Results of laboratory and instrumental examinations: clinical blood test - monocytes

    Leukocyte formula (monocytes, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  45. Results of laboratory and instrumental examinations: clinical blood test - lymphocytes

    Leukocyte formula (lymphocytes, %)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  46. Results of laboratory and instrumental examinations: blood chemistry - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  47. Results of laboratory and instrumental examinations: blood chemistry - cholesterol

    Total cholesterol concentration (mmol/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  48. Results of laboratory and instrumental examinations: blood chemistry - protein

    Total protein concentration (g/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  49. Results of laboratory and instrumental examinations: blood chemistry - bilirubin

    Total bilirubin concentration (micromol/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  50. Results of laboratory and instrumental examinations: blood chemistry - creatinine

    Creatinine concentration (micromol/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  51. Results of laboratory and instrumental examinations: blood chemistry - alkaline phosphatase

    Alkaline phosphatase activity (U/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  52. Results of laboratory and instrumental examinations: blood chemistry - alanine transaminase

    Alanine transaminase activity (U/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  53. Results of laboratory and instrumental examinations: blood chemistry - aspartate transaminase

    Aspartate transaminase activity (U/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  54. Results of laboratory and instrumental examinations: blood chemistry - gamma-GTP

    Gamma-glutaryl transpeptidase activity (U/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  55. Results of laboratory and instrumental examinations: blood chemistry - CRP

    C-reactive protein, CRP (mg/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  56. Results of laboratory and instrumental examinations: urinalysis - specific gravity

    Specific gravity of the urine

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  57. Results of laboratory and instrumental examinations: urinalysis - pH

    pH of the urine

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  58. Results of laboratory and instrumental examinations: urinalysis - protein

    Protein concentration (g/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  59. Results of laboratory and instrumental examinations: urinalysis - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  60. Results of laboratory and instrumental examinations: urinalysis - red blood cells

    Red blood cell content (number in sight)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  61. Results of laboratory and instrumental examinations: urinalysis - white blood cells

    White blood cell content (number in sight)

    Time frame: Screening, day 15 ± 1, day 29 ± 1

  62. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)

    Time frame: Screening, day 1, day 29 ± 1

  63. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)

    Time frame: Screening, day 1, day 29 ± 1

  64. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)

    Time frame: Screening, day 1, day 29 ± 1

  65. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave) (Frederica correction)

    Time frame: Screening, day 1, day 29 ± 1

07

Study locations

10 of 10 sites recruiting
  • State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare"
    Moscow, 117556, Russia
    Recruiting
  • Unimed-C Jsc
    Moscow, 119571, Russia
    Recruiting
  • The State Budgetary Healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
    Moscow, Russia
    Recruiting
  • Limited Liability Company "ErSi Medical"
    Novosibirsk, Russia
    Recruiting
  • Federal State Budgetary Educational Institution of Higher Education "Academician E.A. Wagner Perm State Medical University" of the Ministry of Healthcare of the Russian Federation
    Perm, 614990, Russia
    Recruiting
  • St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117"
    Saint Petersburg, 194358, Russia
    Recruiting
  • Limited Liability Company "Research Center Eco-Safety"
    Saint Petersburg, 196143, Russia
    Recruiting
  • Limited Liability Company "Research Center Eco-Safety"
    Saint Petersburg, 196143, Russia
    Recruiting
  • Limited Liability Company "Clinic Zvezdnaya"
    Saint Petersburg, 196158, Russia
    Recruiting
  • State Healthcare Institution "Saratov City Clinical Hospital No. 5"
    Saratov, 410071, Russia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Dec 12, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07595003
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Dec 12, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion